Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

On Sept 15, Cytokinetics Participates In FDA Late Cycle Meeting For NDA For Aficamten; PDUFA Target Action Date For Aficamten NDA Is Dec 26, 2025; Continues To Expect Differentiated Label & Risk Mitigation Profile For Aficamten If Approved By FDA

Author: Benzinga Newsdesk | September 16, 2025 04:15pm

-SEC Filing

Posted In: CYTK